Good MorningEquities advanced on Thursday, extending the week's Santa Claus Rally to about 0.75%. The rally may continue on Friday, but it looks unlikely we'll see a new all-time high on the S&P 500 until next year. As robust as the outlook is for 2024, there are concerns that earnings growth will not be as good as forecasted and that the FOMC may tip the economy into recession. Because it takes 12 months or longer for FOMC policy changes to take full effect, the impact of rate hikes in the first half of 2023 are still working their way through the system and could cause a marked contraction in activity come January.
The question on every trader's mind is what will happen with the S&P 500 index on Tuesday when the new trading year starts. One risk is that enough traders will sit on the sidelines, waiting to see what happens, causing a self-fulfilling prophecy. In that scenario, downside momentum could build quickly, leading the market into a full-blown correction. Featured: Wall Street’s quietly buying these 3 AI infrastructure plays (Ad) 
|
Auto/Tires/Trucks | |
Penny stocks are attractive simply because of the opportunity for exponential returns. Stocks like Alphabet Inc. (NASDAQ: GOOG), Microsoft Corporation (NASDAQ: MSFT) and Apple Inc. (NASDAQ: AAPL) were once penny stocks but have since provided investor returns counted in quadruple digits.
Here's ... Read the Full Story |
|
From Our Partners | | BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid.
The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | | Get the name, the ticker, and exactly how to buy it |
|
Markets | |
A rising global population has made maintaining viable agricultural space one of the most pressing farming issues of 2024 and beyond. Vertical farming is a solution to this problem. It is the practice of growing crops indoors in stacked layers, utilizing artificial lighting and a controlled enviro... Read the Full Story |
|
Markets | |
Individual retirement accounts (IRAs) offer tax-advantage savings for millions of Americans, but investors must adhere to specific rules to get the benefits. Traditional IRAs offer tax-deductible contributions, while Roth IRAs offer tax-free investment growth.
However, both accounts are subject ... Read the Full Story |
|
From Our Partners | | See the Signals Most Traders Miss
We monitor subtle shifts in order flow, volume patterns, and early trend behavior.
Stock News Trends highlights moves long before they hit mainstream screens. | | Join Free — Start Tracking Early Market Data |
|
Retail/Wholesale | |
As you wander the aisles at your grocery store, staring at the overwhelming number of products on the shelves, you realize that the supermarket is undoubtedly a market of products. Numerous businesses produce, pack and ship these products to you.
After you get the receipt after checking out, it ... Read the Full Story |
|
Consumer Staples | |
A consumer staple ETF (exchange-traded fund) is an investment fund that tracks a series of stocks in companies that produce essential goods and services. The definition of a "consumer staple" usually includes products that consumers typically purchase regardless of economic conditions. Companies t... Read the Full Story |
|
From Our Partners | | With OpenAI and Anthropic moving closer to the IPO spotlight, AI excitement could spill into several public-market sectors this summer - and most investors may chase the obvious names too late.
A free report identifies 7 stocks positioned around themes that could matter most this summer: AI infrastructure, energy demand, travel, entertainment, home improvement, and more. Built for a market where leadership may rotate quickly. | | Download 7 Best Stocks to Own in Summer 2026 for free |
|
Medical | |
Insider buying has been solid in numerous stocks in 2024 with the overarching theme of deep value. The stocks on today’s list offer substantial value relative to their historical prices, and all have a catalyst to drive rebounds in 2024. In addition to insider support, these stocks also have... Read the Full Story |
|
Auto/Tires/Trucks | |
As we head into 2024, the electric vehicle (EV) space remains one of the most closely watched by investors. All told it's had a decent year, but one that's far from its best. The Global X Autonomous & Electric Vehicles ETF (NASDAQ: DRIV) is set to finish 2023 with around a 25% gain, having bee... Read the Full Story |
|
Technology | |
The Dogs of the Dow is a popular strategy getting much attention now that the year-end is here. The theory assumes that this year’s losers will be next year’s winners, which is often true. Dow Dogs offers value and above-average yield, with Walgreens Boots Alliance (NASDAQ: WBA) being ... Read the Full Story |
|
Finance | |
Last quarter, it became evident to thousands of investors just like you just how bullish Ray Dalio had become on Asian markets. Still, while most thought it was a one-time allocation to gain the proper amount of exposure into that section of emerging markets, today, he is proving to be on a much b... Read the Full Story |
|
Technology | |
There’s no doubt about it: equities have had a super strong end to the year, with the Dow Jones index already at fresh all-time highs and the others on its heels. The benchmark S&P 500 index, for example, has returned 16% since the end of October, and the widely used VIX index is close t... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. | | View Today's Stock Pick |
|
